TY - JOUR
T1 - Brain DNA methylomic analysis of frontotemporal lobar degeneration reveals OTUD4 in shared dysregulated signatures across pathological subtypes
AU - Fodder, Katherine
AU - Murthy, Megha
AU - Rizzu, Patrizia
AU - Toomey, Christina E.
AU - Hasan, Rahat
AU - Humphrey, Jack
AU - Raj, Towfique
AU - Lunnon, Katie
AU - Mill, Jonathan
AU - Heutink, Peter
AU - Lashley, Tammaryn
AU - Bettencourt, Conceição
N1 - Funding Information:
The authors would like to thank UCL Genomics centre for advice and processing of the EPIC arrays for the FTLD1 cohort. The authors would also like to acknowledge the Queen Square Brain Bank (London, UK), and the Dutch Brain Bank, Netherlands Institute for Neuroscience (Amsterdam, Netherlands) for providing brain tissues from FTLD cases and controls. The Queen Square Brain Bank is supported by the Reta Lila Weston Institute of Neurological Studies, UCL Queen Square Institute of Neurology. KF is supported by the Medical Research Council (MR/N013867/1). MM is supported by a grant from the Multiple System Atrophy Trust awarded to CB. CB is supported by Alzheimer’s Research UK (ARUK-RF2019B-005) and the Multiple System Atrophy Trust. JH, RH, and TR are supported by NIH NIA R56-AG055824 and U01-AG068880, and NIH NINDS U54NS123743.
Funding Information:
The authors would like to thank UCL Genomics centre for advice and processing of the EPIC arrays for the FTLD1 cohort. The authors would also like to acknowledge the Queen Square Brain Bank (London, UK), and the Dutch Brain Bank, Netherlands Institute for Neuroscience (Amsterdam, Netherlands) for providing brain tissues from FTLD cases and controls. The Queen Square Brain Bank is supported by the Reta Lila Weston Institute of Neurological Studies, UCL Queen Square Institute of Neurology. KF is supported by the Medical Research Council (MR/N013867/1). MM is supported by a grant from the Multiple System Atrophy Trust awarded to CB. CB is supported by Alzheimer’s Research UK (ARUK-RF2019B-005) and the Multiple System Atrophy Trust. JH, RH, and TR are supported by NIH NIA R56-AG055824 and U01-AG068880, and NIH NINDS U54NS123743.
Publisher Copyright:
© 2023, The Author(s).
PY - 2023/7
Y1 - 2023/7
N2 - Frontotemporal lobar degeneration (FTLD) is an umbrella term describing the neuropathology of a clinically, genetically and pathologically heterogeneous group of diseases, including frontotemporal dementia (FTD) and progressive supranuclear palsy (PSP). Among the major FTLD pathological subgroups, FTLD with TDP-43 positive inclusions (FTLD-TDP) and FTLD with tau-positive inclusions (FTLD-tau) are the most common, representing about 90% of the cases. Although alterations in DNA methylation have been consistently associated with neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease, little is known for FTLD and its heterogeneous subgroups and subtypes. The main goal of this study was to investigate DNA methylation variation in FTLD-TDP and FTLD-tau. We used frontal cortex genome-wide DNA methylation profiles from three FTLD cohorts (142 FTLD cases and 92 controls), generated using the Illumina 450K or EPIC microarrays. We performed epigenome-wide association studies (EWAS) for each cohort followed by meta-analysis to identify shared differentially methylated loci across FTLD subgroups/subtypes. In addition, we used weighted gene correlation network analysis to identify co-methylation signatures associated with FTLD and other disease-related traits. Wherever possible, we also incorporated relevant gene/protein expression data. After accounting for a conservative Bonferroni multiple testing correction, the EWAS meta-analysis revealed two differentially methylated loci in FTLD, one annotated to OTUD4 (5’UTR-shore) and the other to NFATC1 (gene body-island). Of these loci, OTUD4 showed consistent upregulation of mRNA and protein expression in FTLD. In addition, in the three independent co-methylation networks, OTUD4-containing modules were enriched for EWAS meta-analysis top loci and were strongly associated with the FTLD status. These co-methylation modules were enriched for genes implicated in the ubiquitin system, RNA/stress granule formation and glutamatergic synaptic signalling. Altogether, our findings identified novel FTLD-associated loci, and support a role for DNA methylation as a mechanism involved in the dysregulation of biological processes relevant to FTLD, highlighting novel potential avenues for therapeutic development.
AB - Frontotemporal lobar degeneration (FTLD) is an umbrella term describing the neuropathology of a clinically, genetically and pathologically heterogeneous group of diseases, including frontotemporal dementia (FTD) and progressive supranuclear palsy (PSP). Among the major FTLD pathological subgroups, FTLD with TDP-43 positive inclusions (FTLD-TDP) and FTLD with tau-positive inclusions (FTLD-tau) are the most common, representing about 90% of the cases. Although alterations in DNA methylation have been consistently associated with neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease, little is known for FTLD and its heterogeneous subgroups and subtypes. The main goal of this study was to investigate DNA methylation variation in FTLD-TDP and FTLD-tau. We used frontal cortex genome-wide DNA methylation profiles from three FTLD cohorts (142 FTLD cases and 92 controls), generated using the Illumina 450K or EPIC microarrays. We performed epigenome-wide association studies (EWAS) for each cohort followed by meta-analysis to identify shared differentially methylated loci across FTLD subgroups/subtypes. In addition, we used weighted gene correlation network analysis to identify co-methylation signatures associated with FTLD and other disease-related traits. Wherever possible, we also incorporated relevant gene/protein expression data. After accounting for a conservative Bonferroni multiple testing correction, the EWAS meta-analysis revealed two differentially methylated loci in FTLD, one annotated to OTUD4 (5’UTR-shore) and the other to NFATC1 (gene body-island). Of these loci, OTUD4 showed consistent upregulation of mRNA and protein expression in FTLD. In addition, in the three independent co-methylation networks, OTUD4-containing modules were enriched for EWAS meta-analysis top loci and were strongly associated with the FTLD status. These co-methylation modules were enriched for genes implicated in the ubiquitin system, RNA/stress granule formation and glutamatergic synaptic signalling. Altogether, our findings identified novel FTLD-associated loci, and support a role for DNA methylation as a mechanism involved in the dysregulation of biological processes relevant to FTLD, highlighting novel potential avenues for therapeutic development.
KW - Co-methylation
KW - DNA methylation
KW - EWAS
KW - Frontotemporal dementia
KW - Human brain tissue
KW - Progressive supranuclear palsy
UR - http://www.scopus.com/inward/record.url?scp=85158085541&partnerID=8YFLogxK
U2 - 10.1007/s00401-023-02583-z
DO - 10.1007/s00401-023-02583-z
M3 - Article
AN - SCOPUS:85158085541
SN - 0001-6322
VL - 146
SP - 77
EP - 95
JO - Acta Neuropathologica
JF - Acta Neuropathologica
IS - 1
ER -